Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Publikation

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Wissenschaftlicher Artikel/Review - 12.12.2023

Sonneveld Pieter, Dimopoulos Meletios A, Boccadoro Mario, Quach Hang, Ho P Joy, Beksac Meral, Hulin Cyrille, Antonioli Elisabetta, Leleu Xavier, Mangiacavalli Silvia, Perrot Aurore, Cavo Michele, Belotti Angelo, Broijl Annemiek, Gay Francesca, Mina Roberto, Nijhof Inger, van de Donk Niels W C J, Katodritou Eirini, Schjesvold Fredrik, Sureda Balari Anna, Rosiñol Laura, Delforge Michel, Roeloffzen Wilfried, Silzle Tobias, Vangsted Annette Juul, Einsele Hermann, Spencer Andrew, Hájek Roman, Jurczyszyn Artur, Lonergan Sarah, Ahmadi Tahamtan, Liu Yanfang, Wang Jianping, Vieyra Diego, van Brummelen Emilie M J, Vanquickelberghe Veronique, Sitthi-Amorn Anna, Van de Velde Cornelis J H, Carson Robin, Rodriguez-Otero Paula, Bladé Joan, Moreau Philippe, PERSEUS Trial Investigators

Zitation

Sonneveld P, Dimopoulos M, Boccadoro M, Quach H, Ho P, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof I, van de Donk N, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hájek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen E, Vanquickelberghe V, Sitthi-Amorn A, Van de Velde C, Carson R, Rodriguez-Otero P, Bladé J, Moreau P, PERSEUS Trial Investigators. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2023; 390:301-313.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

N Engl J Med 2023; 390

Veröffentlichungsdatum

12.12.2023

eISSN (Online)

1533-4406

Seiten

301-313

Kurzbeschreibung/Zielsetzung

Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnosed multiple myeloma is needed.